Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Merck and : Mercks Keynote-119 trial of Keytruda fails to meet primary endpoint

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/24/2019 | 09:03am EDT

Merck has reported that the Phase III Keynote-119 trial evaluating its anti-PD-1 therapy Keytruda as a monotherapy to treat metastatic triple-negative breast cancer (TNBC) did not meet its pre-specified primary endpoint of superior overall survival (OS) compared to chemotherapy.

The company did not formally test other endpoints as the primary endpoint of OS was not met.

The secondary endpoints of the Keynote-119 Phase III randomised clinical trial are progression-free survival, overall response rate, disease control rate and duration of response.

As part of the study, a total of 622 patients were randomised to receive either Keytruda as a monotherapy or physicians choice of single-agent chemotherapy at 1:1 ratio.

The study did not identify any new safety concerns.

Merck Research Laboratories chief medical officer, global clinical development senior vice-president and head Dr Roy Baynes said: Metastatic triple-negative breast cancer is an aggressive and challenging disease to treat, especially after progression on initial standard-of-care treatment.

While we are disappointed by the outcome of this monotherapy trial, we are continuing to study Keytruda in earlier stages of the disease and in combination with chemotherapy to address the unmet medical need of patients with triple negative breast cancer.

The breast cancer clinical development programme covers several internal and external collaborative studies, including three ongoing registration-enabling studies Keynote-355, Keynote-242, and Keynote-522 in TNBC.

The anti-PD-1 therapy Keytruda increases the ability of the bodys immune system to help detect and fight tumour cells.

It blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, and will activate T lymphocytes, which may affect both tumour cells and healthy cells.

(c) 2019 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
09:03aMERCK AND : Mercks Keynote-119 trial of Keytruda fails to meet primary endpoint
AQ
05/23MERCK AND : puts $1B more into oncology, with kidney cancer a focus
AQ
05/23MERCK AND : Mercks Keytruda fails in Phase III triple-negative breast cancer stu..
AQ
05/23MERCK AND : UKs LifeArc charity nets $1.3 billion Keytruda windfall
AQ
05/22MERCK AND : Peloton Therapeutics - Merck to Acquire Peloton Therapeutics, Bolste..
AQ
05/22MERCK FOUNDATION : Announces Grant to American Cancer Society to Improve Access ..
BU
05/21MARKET SNAPSHOT: Dow Logs 200-point Gain As Demand For Tech, Energy Stocks Ov..
DJ
05/21MERCK AND : buys Peloton to expand its kidney cancer treatment portfolio
RE
05/21GLOBAL MARKETS LIVE : Huawei, Sprint, T-Mobile, Tesla…
05/21MERCK AND : to Buy Cancer Drug Maker Peloton Therapeutics -- 2nd Update
DJ
More news
Financials ($)
Sales 2019 44 685 M
EBIT 2019 15 007 M
Net income 2019 10 549 M
Debt 2019 18 245 M
Yield 2019 2,72%
P/E ratio 2019 19,53
P/E ratio 2020 16,90
EV / Sales 2019 5,08x
EV / Sales 2020 4,75x
Capitalization 209 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 89,2 $
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY6.03%208 598
JOHNSON & JOHNSON7.52%371 150
PFIZER-3.80%233 072
ROCHE HOLDING LTD.10.72%230 177
NOVARTIS14.01%212 054
ABBVIE-11.98%119 967